

## Important safety information Drug-Coated Angioplasty Balloon – Stellarex

Caution: Federal law restricts this device to sale by or on the order of a physician.

## Indications for Use

The Stellarex 0.035" OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.

## **Contraindications**

The Stellarex™ 0.035" OTW Drug-coated Angioplasty Balloon is contraindicated for use in:

- Patients with known hypersensitivity to paclitaxel or structurally related compounds.
- Patients who cannot receive recommended antiplatelet and/or anticoagulation therapy.
- Women who are breastfeeding, pregnant or are intending to become pregnant or men intending to father children.
- Coronary arteries, renal arteries, and supra-aortic/cerebrovascular arteries.
- Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the delivery system.

## **Potential Adverse Events**

Possible adverse effects associated with the balloon dilation procedure include, but are not limited to: Abrupt vessel closure; Allergic reaction to contrast medium, antiplatelet therapy, or catheter system components (drug, excipients, and materials); Amputation/Loss of limb; Arrhythmias; Arterial aneurysm; Thrombosis; Arterio-venous fistula (AVF); Bleeding; Death; Embolism/Device embolism; Fever; Hematoma; Hemorrhage; Hypertension/Hypotension; Infection or pain at insertion site; Inflammation; Ischemia or infarction of tissue/organ; Occlusion; Pain or tenderness; Peripheral edema; Pseudoaneurysm; Renal insufficiency or failure; Restenosis; Sepsis or systemic infection; Shock; Stroke/Cerebrovascular accident; Vessel dissection, perforation, rupture, spasm, or recoil; Vessel trauma which requires surgical repair.

Potential complications of peripheral balloon catheterization include, but are not limited to: Balloon rupture; Detachment of a component of the balloon and/or catheter system; Failure of the balloon to perform as intended; Failure to cross the lesion.

Potential complications which may be associated with the addition of paclitaxel to the balloon include, but may not be limited to the following: Allergic/immunologic reaction to paclitaxel; Alopecia; Anemia; Gastrointestinal symptoms (diarrhea, nausea, pain, vomiting); Hematologic dyscrasia (including neutropenia, leucopenia, thrombocytopenia); Hepatic enzyme changes; Histologic changes in vessel wall including inflammation, cellular damage, or necrosis; Myalgia/Arthralgia; Myelosuppression; Peripheral neuropathy.